https://www.thebodypro.com/author/barbara-jungwirth

Latest by Barbara Jungwirth

News

This Week in HIV Research: Gender Disparities Among the Formerly Incarcerated

Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.

News

This Week in HIV Research: A New Frontier in Organ Transplantation

HIV-positive donor, HIV-negative recipient; continuum of care after incarceration in U.S.; reduced bone mineral density among men with HIV under 50; discouraging anti-inflammatory findings for an antiplatelet agent.

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (Delstrigo)
News

Fixed-Dose Doravirine Combination Non-Inferior in Treatment-Experienced Patients

Delstrigo, a fixed-dose combination regimen containing the newly approved antiretroviral doravirine (Pifeltro), lamivudine (3TC, Epivir), and tenofovir disoproxil fumarate (Viread), was non-inferior to other triple combination therapies in participan...

News

This Week in HIV Research: The Case for Pre-Pregnancy Treatment

The benefits of pre-pregnancy HIV treatment initiation for mothers-to-be; HIV diagnoses rise among young U.S. MSM; cost effectiveness of PrEP for heterosexual women; methotrexate and arterial function.

News

This Week in HIV Research: Food, It Does a Body Good

How food insecurity feeds inflammation; racial disparities in HPV16 prevalence; how HIV meds affect pre-existing neurocognitive impairment; central nervous system inflammation in the setting of HIV treatment success.

This Week in HIV Research: Pain, Opioids, and Viral Suppression

Why not all opioid prescriptions are unwise; racial, gender, age, and risk group disparities in HIV care; prophylactic antibiotic use rises among MSM on PrEP; navigating ambiguous HIV test results among PrEP users.

Two New Antiretrovirals Containing Doravirine Approved in the U.S. Img

Two New Antiretrovirals Containing Doravirine Approved in the U.S.

Based on 96-week data from the DRIVE-FORWARD study, the U.S. Food and Drug Administration has approved two new antiretroviral medications ahead of schedule.

News Analysis

This Week in HIV Research: How Antiretrovirals May Affect Birth

The effect of specific regimens on some birth-related events; obstacles to PrEP among U.S. women; improving mortality and treatment success for HIV-positive people who inject drugs; kidney disease and “old” tenofovir.

This Week in HIV Research: Matters of the Mind

Anticholinergics and cognitive performance; gender, physical activity, and cognitive decline; how peer networks can boost HIV self-testing among MSM of color; what HIV care providers don’t know about the Affordable Care Act.

This Week in HIV Research: Where Are the Cervical Cancer Screens?

Poor rates of cervical cancer screening for women of color; interest vs. action among potential organ donors; an online depression intervention; Truvada levels in men’s vs. women’s hair.